Trials / Withdrawn
WithdrawnNCT05287971
Standard of Care Lifestyle Support for Stage III NSCLC Patients
Improving Standard of Care Lifestyle Support for Stage III NSCLC Cancer Patients
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Maastricht Radiation Oncology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Offering an early-initiated supportive care program to stage III NSCLC patients to prevent deterioration of performance status and increase compliance of patients that complete chemoradiation as well as the patients receiving 12 months of durvalumab.
Detailed description
In inoperable Stage III Non-Small Cell Lung Cancer (NSCLC), consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab, given within 6 weeks after completion of concurrent platinum-based chemoradiotherapy (CCRT) for 12 months results in remarkable improvement of 3-year overall survival rates (57% vs 43.5%). This tri-modal therapy has become the new standard of care. Unfortunately, the tri-modal therapy frequently causes adverse events such as fatigue and, to a much lesser degree, cough, dyspnea and pneumonitis, resulting in treatment cessation in 15% - 53% of the patients (15%) (53%). For the most optimal overall survival (OS) and disease-free survival (DFS), compliance to the full treatment regimen, i.e. in the ideal situation 100% of patients completing their full course of CCRT and receiving durvalumab for one year, is expected to have significant and relevant beneficial effects. Optimizing patients' fitness is essential in order to handle the tough full treatment regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Lifestyle advice | Patients will receive lifestyle advice regarding nutricion and exercise and will be monitored with regard to exercise and vital signs. |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2024-05-01
- Completion
- 2025-05-01
- First posted
- 2022-03-18
- Last updated
- 2023-09-06
Source: ClinicalTrials.gov record NCT05287971. Inclusion in this directory is not an endorsement.